Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132418
Status:
COMPLETED
Last Update Posted:
2011-01-21
First Post:
2005-08-19
Brief Title:
Study of Enbrel in Rheumatoid Arthritis RA Subjects With Comorbid Disorders
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Double-blind Randomized Placebo-controlled Study of Enbrel Etanercept in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to evaluate the safety of Enbrel etanercept in rheumatoid arthritis RA subjects with greater than or equal to 1 documented comorbid disease diabetes mellitus chronic pulmonary disease pneumonia within the last year or recurrent bronchitis sinusitis or urinary tract infection that might increase infection risk
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None